SAMPLE FOR DIRECTLY SPONSORED ACTIVITIES

DREXEL UNIVERSITY COLLEGE OF MEDICINE

THERAPEUTIC TARGETING OF EPILEPTOGENESIS

Department of Neurology Grand Rounds

February 21, 2011 ~ 10:00 AM

Lecture Hall B - New College Building, 2nd Floor
SE Corner of 15th and Vine Streets
Philadelphia, PA

Jane Sample, M.D.
Associate Professor, Pediatrics, Neurology and Neuroscience
Abramson Research Center, Children’s Hospital of Philadelphia
Philadelphia, PA

Target Audience:
- Attending and Visiting Physicians
- Residents
- Medical Students

Objectives:
- Describe mechanisms regulating the development of epilepsy
- Discuss possible intervention strategies to block epilepsy development
- Explain the possible utility of transcriptional depressors in epilepsy

Accreditation Statement
Drexel University College of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA Credit Designation Statement: The Drexel University College of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s) ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AOA: This program is eligible for 1 credit in Category 2A of the American Osteopathic Association.

Faculty Disclosure Statement
Speakers at continuing medical education activities are required to disclose to the audience any financial relationships with the manufacturer(s) of any commercial products, goods or services. Any conflicts of interest must be resolved prior to the presentation and announced to the audience.

Faculty Disclosure: Dr. Jane Sample is a consultant with Sanofi Aventis. Dr. Sample will support the presentation and clinical recommendations with the “best available evidence” from the medical literature. Planning Committee Members: Drs. Shields, Barnes and Foe have no commercial relationships to disclose. or Dr. Sample has no commercial relationships to disclose.

This activity is supported by an educational grant from Wyeth Pharmaceuticals